טוען...
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Breezhaler), often called QVA149, was first approved in 2013 in Japan and Europe. As of November 2014, more than 40 countries had approved this medication except for the USA. This is t...
שמור ב:
| הוצא לאור ב: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4410821/ https://ncbi.nlm.nih.gov/pubmed/25960646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S56067 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|